{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:33:30Z","timestamp":1792204410067,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AI145332"],"award-info":[{"award-number":["5R01AI145332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AI145332"],"award-info":[{"award-number":["5R01AI145332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08830-1","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:12:40Z","timestamp":1759752760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-3740","authenticated-orcid":false,"given":"Xueyong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Piepenbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4025-2646","authenticated-orcid":false,"given":"Wenli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-2419","authenticated-orcid":false,"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-0272","authenticated-orcid":false,"given":"James J.","family":"Kobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"8830_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/cid\/ciz411","volume":"69","author":"EA Belongia","year":"2019","unstructured":"Belongia, E. A. & McLean, H. Q. Influenza vaccine effectiveness: defining the H3N2 problem. Clin. Infect. Dis. 69, 1817\u20131823 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"8830_CR2","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.chom.2023.09.012","volume":"31","author":"KE Kistler","year":"2023","unstructured":"Kistler, K. E. & Bedford, T. An atlas of continuous adaptive evolution in endemic human viruses. Cell Host Microbe 31, 1898\u20131909.e1893 (2023).","journal-title":"Cell Host Microbe"},{"key":"8830_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/cid\/ciac941","volume":"76","author":"AM Price","year":"2023","unstructured":"Price, A. M. et al. Influenza vaccine effectiveness against influenza A(H3N2)-related illness in the United States during the 2021-2022 influenza season. Clin. Infect. Dis. 76, 1358\u20131363 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"8830_CR4","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1093\/infdis\/jiaa685","volume":"223","author":"ET Martin","year":"2021","unstructured":"Martin, E. T. et al. Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016-2017 and 2017-2018 of the hospitalized adult influenza vaccine effectiveness network (HAIVEN). J. Infect. Dis. 223, 2062\u20132071 (2021).","journal-title":"J. Infect. Dis."},{"key":"8830_CR5","doi-asserted-by":"publisher","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","volume":"13","author":"NC Wu","year":"2017","unstructured":"Wu, N. C. et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 13, e1006682 (2017).","journal-title":"PLoS Pathog."},{"key":"8830_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1073\/pnas.87.2.786","volume":"87","author":"ED Kilbourne","year":"1990","unstructured":"Kilbourne, E. D., Johansson, B. E. & Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA 87, 786\u2013790 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8830_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"8830_CR8","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.antiviral.2023.105785","volume":"221","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. Broadly neutralizing antibodies to combat influenza virus infection. Antivir. Res. 221, 105785 (2024).","journal-title":"Antivir. Res."},{"key":"8830_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D: Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D: Struct. Biol."},{"key":"8830_CR10","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41564-019-0522-6","volume":"4","author":"H Wan","year":"2019","unstructured":"Wan, H. et al. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A\/Hong Kong\/4801\/2014 vaccine strain. Nat. Microbiol. 4, 2216\u20132225 (2019).","journal-title":"Nat. Microbiol."},{"key":"8830_CR11","doi-asserted-by":"publisher","first-page":"e1008411","DOI":"10.1371\/journal.ppat.1008411","volume":"16","author":"H Powell","year":"2020","unstructured":"Powell, H. & Pekosz, A. Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding. PLoS Pathog. 16, e1008411 (2020).","journal-title":"PLoS Pathog."},{"key":"8830_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35586-7","volume":"13","author":"D Stadlbauer","year":"2022","unstructured":"Stadlbauer, D. et al. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Nat. Commun. 13, 7864 (2022).","journal-title":"Nat. Commun."},{"key":"8830_CR13","doi-asserted-by":"publisher","first-page":"e1011554","DOI":"10.1371\/journal.ppat.1011554","volume":"19","author":"K Tonouchi","year":"2023","unstructured":"Tonouchi, K. et al. Structural basis for cross-group recognition of an influenza virus hemagglutinin antibody that targets postfusion stabilized epitope. PLoS Pathog. 19, e1011554 (2023).","journal-title":"PLoS Pathog."},{"key":"8830_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08165-y","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. Nat. Commun. 10, 324 (2019).","journal-title":"Nat. Commun."},{"key":"8830_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fimmu.2018.00865","volume":"9","author":"SB Morgan","year":"2018","unstructured":"Morgan, S. B. et al. Therapeutic administration of broadly neutralizing FI6 antibody reveals lack of interaction between human IgG1 and pig Fc receptors. Front Immunol. 9, 865 (2018).","journal-title":"Front Immunol."},{"key":"8830_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","volume":"20","author":"DJ DiLillo","year":"2014","unstructured":"DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143\u2013151 (2014).","journal-title":"Nat. Med."},{"key":"8830_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"8830_CR18","doi-asserted-by":"publisher","first-page":"eade4790","DOI":"10.1126\/scitranslmed.ade4790","volume":"15","author":"AT Widge","year":"2023","unstructured":"Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).","journal-title":"Sci. Transl. Med."},{"key":"8830_CR19","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.immuni.2023.10.005","volume":"56","author":"R Lei","year":"2023","unstructured":"Lei, R. et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity 56, 2621\u20132634.e2626 (2023).","journal-title":"Immunity"},{"key":"8830_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-023-06136-y","volume":"618","author":"C Momont","year":"2023","unstructured":"Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature 618, 590\u2013597 (2023).","journal-title":"Nature"},{"key":"8830_CR21","doi-asserted-by":"publisher","first-page":"e0472822","DOI":"10.1128\/spectrum.04728-22","volume":"11","author":"M Piepenbrink","year":"2023","unstructured":"Piepenbrink, M. et al. Highly cross-reactive and protective influenza A virus H3N2 hemagglutinin- and neuraminidase-specific human monoclonal antibodies. Microbiol. Spectr. 11, e0472822 (2023).","journal-title":"Microbiol. Spectr."},{"key":"8830_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/303041a0","volume":"303","author":"PM Colman","year":"1983","unstructured":"Colman, P. M., Varghese, J. N. & Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41\u201344 (1983).","journal-title":"Nature"},{"key":"8830_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/j.1460-2075.1992.tb05026.x","volume":"11","author":"WP Burmeister","year":"1992","unstructured":"Burmeister, W. P., Ruigrok, R. W. & Cusack, S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11, 49\u201356 (1992).","journal-title":"EMBO J."},{"key":"8830_CR24","doi-asserted-by":"publisher","first-page":"e02315","DOI":"10.1128\/mBio.02315-20","volume":"11","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. Structure-based modification of an anti-neuraminidase human antibody restores protection efficacy against the drifted influenza virus. mBio 11, e02315\u2013e02320 (2020).","journal-title":"mBio"},{"key":"8830_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.immuni.2020.08.015","volume":"53","author":"A Madsen","year":"2020","unstructured":"Madsen, A. et al. Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity 53, 852\u2013863.e857 (2020).","journal-title":"Immunity"},{"key":"8830_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.chom.2019.10.002","volume":"26","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Structural basis of protection against H7N9 influenza virus by human anti-N9 neuraminidase antibodies. Cell Host Microbe 26, 729\u2013738.e724 (2019).","journal-title":"Cell Host Microbe"},{"key":"8830_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/35018508","volume":"406","author":"P Sondermann","year":"2000","unstructured":"Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267\u2013273 (2000).","journal-title":"Nature"},{"key":"8830_CR28","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","volume":"164","author":"EE Idusogie","year":"2000","unstructured":"Idusogie, E. E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178\u20134184 (2000).","journal-title":"J. Immunol."},{"key":"8830_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34521-0","volume":"13","author":"A Yasuhara","year":"2022","unstructured":"Yasuhara, A. et al. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat. Commun. 13, 6602 (2022).","journal-title":"Nat. Commun."},{"key":"8830_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62174-2","volume":"16","author":"G Jo","year":"2025","unstructured":"Jo, G. et al. Structural basis of broad protection against influenza virus by human antibodies targeting the neuraminidase active site via a recurring motif in CDR H3. Nat. Commun. 16, 7067 (2025).","journal-title":"Nat. Commun."},{"key":"8830_CR31","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","volume":"119","author":"P Bruhns","year":"2012","unstructured":"Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640\u20135649 (2012).","journal-title":"Blood"},{"key":"8830_CR32","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8830_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs 9, 767\u2013773 (2017).","journal-title":"MAbs"},{"key":"8830_CR34","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","volume":"292","author":"M Lo","year":"2017","unstructured":"Lo, M. et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J. Biol. Chem. 292, 3900\u20133908 (2017).","journal-title":"J. Biol. Chem."},{"key":"8830_CR35","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson, I. et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE 16, e0260954 (2021).","journal-title":"PLoS ONE"},{"key":"8830_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126, 605\u2013610 (2016).","journal-title":"J. Clin. Invest."},{"key":"8830_CR37","doi-asserted-by":"publisher","first-page":"873191","DOI":"10.3389\/fimmu.2022.873191","volume":"13","author":"BM Motsoeneng","year":"2022","unstructured":"Motsoeneng, B. M. et al. Influenza vaccination results in differential hemagglutinin stalk-specific Fc-mediated functions in individuals living with or without HIV. Front. Immunol. 13, 873191 (2022).","journal-title":"Front. Immunol."},{"key":"8830_CR38","doi-asserted-by":"publisher","first-page":"10493","DOI":"10.1128\/JVI.00959-08","volume":"82","author":"X Xu","year":"2008","unstructured":"Xu, X., Zhu, X., Dwek, R. A., Stevens, J. & Wilson, I. A. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 82, 10493\u201310501 (2008).","journal-title":"J. Virol."},{"key":"8830_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1107\/S0907444906019949","volume":"62","author":"W Minor","year":"2006","unstructured":"Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr. D: Biol. Crystallogr. 62, 859\u2013866 (2006).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"8830_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"8830_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D: Biol. Crystallogr. 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"8830_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D: Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"8830_CR43","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"8830_CR44","doi-asserted-by":"publisher","first-page":"909297","DOI":"10.3389\/fimmu.2022.909297","volume":"13","author":"MC Bernard","year":"2022","unstructured":"Bernard, M. C. et al. Validation of a harmonized enzyme-linked-lectin-assay (ELLA-NI) based neuraminidase inhibition assay standard operating procedure (SOP) for quantification of N1 influenza antibodies and the use of a calibrator to improve the reproducibility of the ELLA-NI with reverse genetics viral and recombinant neuraminidase antigens: a FLUCOP collaborative study. Front. Immunol. 13, 909297 (2022).","journal-title":"Front. Immunol."},{"key":"8830_CR45","first-page":"5570","volume":"15","author":"SK Leang","year":"2017","unstructured":"Leang, S. K. & Hurt, A. C. Fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza viruses to the neuraminidase inhibitor class of antivirals. J. Vis. Exp. 15, 5570 (2017).","journal-title":"J. Vis. Exp."},{"key":"8830_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"8830_CR47","doi-asserted-by":"publisher","first-page":"e1010691","DOI":"10.1371\/journal.ppat.1010691","volume":"18","author":"MS Piepenbrink","year":"2022","unstructured":"Piepenbrink, M. S. et al. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog. 18, e1010691 (2022).","journal-title":"PLoS Pathog."},{"key":"8830_CR48","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.1128\/JVI.01081-13","volume":"87","author":"SF Baker","year":"2013","unstructured":"Baker, S. F. et al. Protection against lethal influenza with a viral mimic. J. Virol. 87, 8591\u20138605 (2013).","journal-title":"J. Virol."},{"key":"8830_CR49","doi-asserted-by":"crossref","unstructured":"Khalil, A. M. et al. Fc-effector-independent in vivo activity of a potent influenza b neuraminidase broadly neutralizing antibody. Viruses 15 (2023).","DOI":"10.3390\/v15071540"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08830-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:10:05Z","timestamp":1759756205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08830-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8830"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08830-1","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.S.P., L.M.-S. and J.J.K. are inventors with patent application WO2021202235A1 held by the University of Rochester, which covers the mAbs described in this manuscript. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1427"}}